MARABELLO, Grazia
 Distribuzione geografica
Continente #
NA - Nord America 569
EU - Europa 501
AS - Asia 159
SA - Sud America 1
Totale 1.230
Nazione #
US - Stati Uniti d'America 569
IE - Irlanda 134
SE - Svezia 134
CN - Cina 94
GB - Regno Unito 50
SG - Singapore 48
IT - Italia 43
PL - Polonia 42
UA - Ucraina 33
DE - Germania 21
FI - Finlandia 19
BE - Belgio 13
IN - India 8
VN - Vietnam 5
IQ - Iraq 3
NL - Olanda 3
RU - Federazione Russa 3
AT - Austria 2
SK - Slovacchia (Repubblica Slovacca) 2
CL - Cile 1
FR - Francia 1
ID - Indonesia 1
NO - Norvegia 1
Totale 1.230
Città #
Dublin 134
Chandler 104
Nyköping 76
Jacksonville 72
Ann Arbor 58
Ashburn 48
Warsaw 42
Singapore 39
Beijing 36
Messina 30
Lancaster 29
Dearborn 28
Medford 19
Princeton 19
Cambridge 18
Des Moines 18
Brussels 13
Boardman 11
Los Angeles 11
Woodbridge 11
Jinan 8
New York 8
Nanjing 7
Shenyang 7
Houston 6
Pune 5
Tianjin 5
Wilmington 5
Dong Ket 4
Jiaxing 4
San Mateo 4
Auburn Hills 3
Guangzhou 3
Hyderabad 3
Najaf 3
Seattle 3
Chicago 2
Clearwater 2
Hebei 2
Helsinki 2
Nanchang 2
Polomka 2
Redwood City 2
Scarsdale 2
Taizhou 2
Vienna 2
Washington 2
Zhengzhou 2
Atlanta 1
Bremen 1
Changsha 1
Fuzhou 1
Haikou 1
Hanoi 1
Jakarta 1
Lanzhou 1
Leawood 1
Mesa 1
Newark 1
Norwalk 1
Novokuznetsk 1
Oslo 1
Riva 1
Saint Petersburg 1
Santa Clara 1
Santiago 1
Shanghai 1
Stezzano 1
Taiyuan 1
Tangshan 1
Trento 1
Wenzhou 1
Totale 942
Nome #
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 111
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 96
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 88
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 84
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 82
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 82
[Serum levels of copper and zinc in patients with lung cancer] 76
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 69
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 66
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 66
Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer 56
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy 56
La farmacogenomica nei tumori del polmone 54
Serum levels of copper and zinc in patients with lung cancer 51
Gemcitabine combined with Oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma 50
Use of bisphosphonates in oncology 50
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 45
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 44
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 38
Totale 1.264
Categoria #
all - tutte 4.798
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.798


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020126 0 0 0 0 4 24 22 14 2 32 21 7
2020/2021185 18 6 30 11 24 16 9 15 8 30 10 8
2021/2022170 0 22 10 3 8 3 14 6 1 40 19 44
2022/2023414 29 61 23 20 30 42 4 20 164 4 13 4
2023/2024102 6 14 6 24 6 33 0 2 0 6 1 4
2024/202566 6 7 9 31 13 0 0 0 0 0 0 0
Totale 1.264